Stock Markets September 15, 2026 08:56 AM

Tenet Healthcare Shares Retreat After Director Sells $2.63 Million Stake

Director Richard Mark disposed of 10,000 shares on Sept. 10; filing gives limited detail as stock slips in premarket trading

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
THC

Tenet Healthcare shares fell 2.3% in premarket trading after a company director, Richard Mark, sold 10,000 shares on September 10. The Form 4 filing shows a weighted average sale price of $263.42 per share, totaling roughly $2.63 million. The filing offered no specific reason for the sale and notes the trades occurred through an attorney-in-fact arrangement with Chad J. Wiener.

Tenet Healthcare Shares Retreat After Director Sells $2.63 Million Stake
THC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Richard Mark sold 10,000 shares on Sept. 10 at a weighted average price of $263.42, totaling about $2.63 million.
  • Sale prices ranged from $263.15 to $264.03; Mark retains beneficial ownership of 25,121 shares after the sale.
  • Transaction executed through an attorney-in-fact arrangement with Chad J. Wiener; filing did not state a reason.

Shares of Tenet Healthcare Corporation (NYSE:THC) declined 2.3% in premarket trading on Tuesday following a disclosure that a company director sold a portion of his stake.

According to a Form 4 filing with the Securities and Exchange Commission, director Richard Mark sold 10,000 shares of Tenet Healthcare common stock on September 10. The filing lists a weighted average price of $263.42 per share for the trades, producing a total transaction value of approximately $2.63 million.

The filing indicates the shares were sold across multiple trades at prices ranging from $263.15 to $264.03 per share. After the sale, Mark retains beneficial ownership of 25,121 shares of Tenet Healthcare common stock. The transaction was processed via an attorney-in-fact arrangement with Chad J. Wiener, the filing shows.

The Form 4 did not include a stated reason for the sale. The filing note underscores that insider transactions can occur for a variety of reasons and do not necessarily indicate the insider's view of the company’s future performance.

Tenet Healthcare operates a network of hospitals and other healthcare facilities across the United States.


Summary

Tenet Healthcare's stock dipped in premarket trading after a director, Richard Mark, sold 10,000 shares on September 10 at a weighted average price of $263.42, totaling roughly $2.63 million. The sale, executed through an attorney-in-fact arrangement with Chad J. Wiener, came in multiple transactions priced between $263.15 and $264.03 per share. Post-transaction, Mark holds 25,121 shares. The filing did not specify a reason for the sale.

Key points

  • Director Richard Mark sold 10,000 Tenet Healthcare shares on September 10 at a weighted average price of $263.42 per share, for approximately $2.63 million in proceeds.
  • Sale prices ranged from $263.15 to $264.03; after the transaction Mark retains beneficial ownership of 25,121 shares.
  • The transaction was executed through an attorney-in-fact arrangement with Chad J. Wiener; the filing provided no reason for the sale.

Risks and uncertainties

  • The filing did not state why the shares were sold, leaving uncertainty about any personal or financial motivations behind the transaction - this affects investor interpretation in the healthcare and broader equity markets.
  • Insider sales can be interpreted in different ways by market participants; the immediate premarket price reaction demonstrates potential short-term volatility for Tenet Healthcare stock.
  • The use of an attorney-in-fact arrangement to execute the sale may add procedural opacity for some investors assessing timing and intent, which can influence trading activity in healthcare equities.

Investors seeking to understand the implications of the filing should note that the Form 4 records the mechanics of the transaction but did not offer commentary or rationale from the director. Tenet Healthcare remains an operator of hospitals and healthcare facilities across the United States.

Risks

  • Filing provided no reason for the sale, introducing uncertainty about motives and market interpretation - impacts healthcare and equity market sentiment.
  • Insider sales can prompt short-term stock volatility, as seen in the 2.3% premarket decline.
  • Use of an attorney-in-fact arrangement may add procedural opacity that some investors view as increasing uncertainty in trading behavior for the stock.

More from Stock Markets

Maria Ressa Urges Immediate Limits on AI to Preserve Human Agency Sep 15, 2026 Forgent Power Solutions Rises Sharply in Pre-Market After Fiscal 2026 Results Sep 15, 2026 Nokia Shares Rebound Pre-Market as Analyst Upgrade and Index Reentry Support the Bounce Sep 15, 2026 BofA Lifts U.S. Semiconductor Growth Forecast to 18% CAGR Through 2030 Sep 15, 2026 Goldman Sachs Sees 25bp Fed Rate Increase, Expects No Forward Guidance Sep 15, 2026